Effects of angiotensin-converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy

American Journal of Cardiology

Volumn 80, Issue 3 A, 1997, Pages 110A-117A

  Zhu, Yi Chun ^a,b,c   Zhu, Yi Zhun ^a,b,c   Gohlke, Peter ^a,b,c   Stauss, Harald M ^a,b,c   Unger, Thomas ^a,b,c  

^a UNIVERSITY OF KIEL   (Germany)

^b FUDAN UNIVERSITY   (China)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; RAMIPRIL;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE;

EID: 0030797885     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00465-7     Document Type: Conference Paper

References (65)

1. Weber KT, Brilla CG, Janicki JS. Signals for the remodelling of the cardiac interstitium in systemic hypertension. J Cardiovasc Pharmacol. 17:((suppl)):1991;S14-S19.
2. Katz AM. Cardiomyopathy of overload. N Engl J Med. 322:1990;100-110.
3. Tomanek RJ, Hovanec JM. The effects of long-term pressure-overload and aging in the myocardium. J Mol Cell Cardiol. 13:1981;471-488.
4. Messerli FH, Ketelhut R. Left ventricular hypertrophy: an independent risk factor. J Cardiovasc Pharmacol. 17:((suppl)):1991;S59-S67.
5. Schultheiss HP. Effect on the myocardial energy metabolism of angiotensin-converting enzyme inhibition in chronic heart failure. Am J Cardiol. 65:1990;G74-G81.
6. Holubarsch Ch, Litten RZ, Mulieri LA, Alpert NR. Energetic changes of myocardium as an adaptation to chronic hemodynamic overload and thyroid gland activity. Bas Res Cardiol. 80:1985;582-593.
7. Soubrier F, Alhenc-Gelas F, Hubert C, Allegrini J, John M, Tregear G, Corvol P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA. 85:1988;9386-9390.
8. Yang HYT, Erdös EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophy Acta. 214:1970;374-376.
9. Hirsch A, Talsness C, Schunkert H, Paul M, Dzau V. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 69:1991;475-482.
10. Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss H, Danilov S, Unger T. Cellular distribution of angiotensin converting enzyme after myocardial infarction. Hypertension. 25:1995;219-226.
11. Sun Y, Weber KT. Angiotensin II receptor binding following myocardial infarction in the rat. Cardiovasc Res. 28:1994;1623-1628.
12. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
13. 2 receptor stimulates phosphotyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase. Biochem Biophys Res Commun. 183:1992;206-211.
14. 2. Biochem Biophys Res Commun. 198:1994;60-66.
15. 2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 95:1995;651-657.
16. 1 receptor mRNA in vascular smooth muscle cells in vitro. (Abstr.) Seventh European Meeting on Hypertension, Milan, 1995;209.
17. 2 receptors in the acute phase of myocardial infarction. (Abstr.). Hypertension. 28:1996;541.
18. Shapiro R, Riordan JF. Inhibition of angiotensin converting enzyme: mechanism and substrate dependence. Biochemistry. 23:1984;5225-5233.
19. Gohlke P, Bünning P, Unger T. Distribution and metabolism of angiotensin I and II in the blood vessel wall. Hypertension. 20:1992;151-157.
20. Unger T, Gohlke P. Converting enzyme inhibitors in cardiovascular therapy: current status and future potential. Cardiovasc Res. 28:1994;146-158.
21. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 23:1994;411-418.
22. Gohlke P, Kuwer I, Bartenbach S, Schnell A, Unger T. Effect of low-dose treatment with perindopril on cardiac function in stroke-prone spontaneously hypertensive rats: role of bradykinin. J Cardiovasc Pharmacol. 24:1994b;462-469.
23. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 47:1995;25-49.
24. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 44:1992;4-80.
25. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger T. Hoe 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol. 200:1991;179-182.
26. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke ST, Breipohl G, König W, Knolle J, Schölkens BA. Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102:769-733; 1991.
27. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke ST, Breipohl G, König W, Knolle J, Schölkens BA. Hoe 140, a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 102:1991;769-773.
28. Burnier M, Brunner HR. Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 3:1994;537-545.
29. Dickstein K, Gottlieb S, Fleck E, Kostis J, Leviene B, Dekock M, LeJemtel T. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens. 12:1994;S31-S31.
30. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol. 26:1995;233-240.
31. Unger T, Chung O, Csikos T, Culman J, Gallinant S, Gohlke P, Hölle S, Meffert S, Stoll M, Stroth U, Zhu YZ. Angiotensin receptors. J Hypertens. 14:((suppl 5)):1996;S95-S103.
32. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 57:1985;84-95.
33. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown E, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. on behalf of the SAVE investigators. Effect of captopril on morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med. 327:1992;669-677.
34. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302.
35. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
36. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation. 65:1982;40-48.
37. Hartmann JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol. 234:1993;229-236.
38. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, Unger T. ACE inhibitors in infarct-induced heart failure: bradykinin versus angiotensin II. J Cardiovasc Risk. 1:1994;255-262.
39. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Unger T. Mechanisms involved in the reduction of infarct size by ACE inhibition after left coronary artery ligation in rats. (Abstr.). J Hypertens. 12:((suppl 3)):1994;2.
40. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol. 182:1990;395-396.
41. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 20:1992;772-778.
42. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res. 62:1988;757-765.
43. Weber KT, Pick R, Jalil JE, Janicki JS, Caroll EP. Pattern of myocardial fibrosis. J Mol Cell Cardiol. 21:((suppl 5)):1989;121-131.
44. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 67:1990;1355-1364.
45. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res. 67:1990;787-794.
46. Callens-EI AF, Paolaggi F, Swynghedauw B. TRemodelling of the heart in DOCA-salt hypertensive rats by propranolol and by an α -2 agonist, rilmenidine. J Hypertens. 7:1989;947-954.
47. Schelling P, Ganten D, Speck G, Fischer H. Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol. 98:1979;503-513.
48. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 25:1993;563-575.
49. Beinlich CJ, White GJ, Baker KM, Morgan HE. Angiotensin II and left ventricular growth in newborn pig heart. J Mol Cell Cardiol. 23:1991;1031-1038.
50. Khairallah PA, Kanabus J. Angiotensin and myocardial protein synthesis. Tarazi RC, Dundar JC. Perspectives in Cardiovascular Research. 8:1983;337-347 Raven Press, New York.
51. Morton JJ, Beattle EC, MacPherson F. Treatment of young spontaneously hypertensive rats (SHR) with angiotensin receptor antagonist losartan reduces hypertension and vascular hypertrophy in adulthood. J Hypertens. 10:((suppl 4)):1992;S151.
52. Oddie CJ, Dilley RJ, Bobik A. Long term angiotensin II antagonism in spontaneously hypertensive rats: effects on blood pressure and cardiovascular amplifiers. Clin Exp Pharmacol Physiol. 19:1992;392-395.
53. Gohlke P, Linz W, Schölkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 28:1996;397-402.
54. Baker KM, Dostal DE, Chernin MI, Wealand AL, Conrad KM. Angiotensin II-mediated cardiac hypertrophy in adult rats. J Cell Biochem. 15C:1991;167.
55. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 11:1989;1325-1350.
56. Kato H, Suzuki H, Tajima S. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens. 9:1991;7-22.
57. 2-bradykinin receptor antagonist Hoe 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 35:1992;771-772.
58. Crisman RP, Rittmann B, Tomanek RJ. Exercise-induced myocardial growth in the spontaneously hypertensive rat. Microvasc Res. 30:1985;185-194.
59. Fulton WFM. The Coronary Arteries. 1965;Thomas, Springfield, IL.
60. Unger T, Mattfeldt T, Lamberty V, Bock P, Mall G, Linz W, Schölkens BA, Gohlke P. Effect of early onset of angiotensin converting enzyme inhibition on myocardial capillaries. Hypertension. 20:1992;478-482.
61. Metsärinne KP, Stoll M, Gohlke P, Paul M, Unger T. Angiotensin II is antiproliferative for coronary endothelial cells in vitro. Pharm Pharmacol Lett. 2:1992;150-152.
62. Schölkens BA, Linz W, König W. Effects of the angiotensin-converting enzyme inhibitor, ramipril, in isolated ischemic heart are abolished by a bradykinin antagonist. J Hypertens. 6:((suppl 4)):1988;S25-S28.
63. Mall G, Zimmer G, Baden S, Mattfeld T. Capillary neoformation in the rat heart - stereological studies on papillary muscles in hypertrophy and physiologic heart. Basic Res Cardiol. 85:1990;531-540.
64. 2-receptors prevents the increase in capillary density induced by chronic ACE inhibitor treatment in stroke prone spontaneously hypertensive rats. Hypertension. 29:1997;478-482.
65. 2 receptor: searching for signal-transduction pathways and physiologic function. Trends Pharmacol Sci. 16:1995;223-225.